Asset Details
Do you wish to reserve the book?
The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation
Do you wish to request the book?
The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation
2020
Overview
Epstein-Barr virus (EBV) reactivation can lead to serious complications in kidney transplant patients, including post-transplant lymphoproliferative disorder (PTLD). Here, we have assessed the impact of EBV on B cell homeostasis at cellular and humoral level. In a multicenter study monitoring 540 kidney transplant patients during the first post-transplant year, EBV reactivation was detected in 109 patients. Thirteen soluble factors and B cell counts were analyzed in an EBV
+
sub-cohort (N = 54) before, at peak and after EBV clearance and compared to a control group (N = 50). The B cell activating factor (BAFF) was significantly elevated among EBV
+
patients. No additional soluble factors were associated with EBV. Importantly, in vitro experiments confirmed the proliferative effect of BAFF on EBV-infected B cells, simultaneously promoting EBV production. In contrast, elevated levels of BAFF in EBV
+
patients did not lead to B cell expansion in vivo. Moreover, diminished positive inter-correlations of soluble factors and alterations of the bi-directional interplay between B cell and soluble factors were observed in EBV
+
patients at peak and after clearance. Our data suggest that such alterations may counteract the proliferative effect of BAFF, preventing B cell expansion. The role of these alterations in lymphoma development should be analyzed in future studies.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ B-Cell Activating Factor - blood
/ B-Cell Activating Factor - metabolism
/ B-Cell Activating Factor - pharmacology
/ B-Lymphocytes - drug effects
/ Epstein-Barr Virus Infections - etiology
/ Epstein-Barr Virus Infections - immunology
/ Female
/ Humanities and Social Sciences
/ Humans
/ Kidney Transplantation - adverse effects
/ Lymphoma
/ Male
/ Posttransplant lymphoproliferative disorders
/ Science
